PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Akebia Therapeutics, Inc. (AKBA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00972D1054
CUSIP00972D105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$230.56M
EPS-$0.22
PE Ratio17.56
Revenue (TTM)$187.22M
Gross Profit (TTM)$140.04M
EBITDA (TTM)$3.97M
Year Range$0.78 - $2.48
Target Price$5.00
Short %5.72%
Short Ratio2.76

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Akebia Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Akebia Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%200.00%December2024FebruaryMarchAprilMay
-95.99%
183.44%
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Akebia Therapeutics, Inc. had a return of -13.71% year-to-date (YTD) and -5.31% in the last 12 months. Over the past 10 years, Akebia Therapeutics, Inc. had an annualized return of -26.87%, while the S&P 500 had an annualized return of 10.70%, indicating that Akebia Therapeutics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-13.71%11.24%
1 month-20.15%4.04%
6 months11.46%16.49%
1 year-5.31%26.17%
5 years (annualized)-26.05%13.76%
10 years (annualized)-26.87%10.70%

Monthly Returns

The table below presents the monthly returns of AKBA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202435.48%-5.95%15.82%-31.15%-13.71%
20239.19%33.76%-33.50%62.12%14.47%-12.02%82.51%-16.77%-17.99%-22.81%20.45%16.98%114.90%
2022-11.95%8.54%-66.76%-42.16%-10.91%-4.54%10.73%-6.83%-13.20%-19.51%6.29%113.31%-74.47%
202115.71%6.79%-2.17%-5.76%10.03%7.98%-34.83%19.03%-2.04%-0.35%-5.57%-16.61%-19.29%
202014.24%22.85%-14.54%6.86%43.70%16.67%-17.75%-6.80%-75.89%-11.55%49.10%-15.41%-55.70%
2019-0.36%32.12%12.50%-26.25%-26.32%8.76%-13.43%-1.43%-5.08%-4.85%68.63%0.48%14.29%
2018-0.61%-3.25%-33.36%-3.36%6.62%1.63%3.21%-20.29%7.55%-15.18%7.88%-31.56%-62.81%
2017-3.65%-0.10%-8.18%43.26%1.67%7.24%-8.21%26.91%17.50%-7.73%-14.27%-4.43%42.84%
2016-43.27%-0.41%23.42%4.22%-5.11%-16.05%19.65%-9.16%11.32%-16.91%14.49%20.91%-19.43%
2015-11.77%-9.83%19.98%-30.96%2.48%30.92%-8.65%-25.96%38.79%-7.66%20.29%20.41%11.00%
2014-26.73%24.59%-0.29%14.36%-20.33%1.67%-1.69%-41.44%-6.79%-3.64%-56.40%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of AKBA is 40, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of AKBA is 4040
AKBA (Akebia Therapeutics, Inc.)
The Sharpe Ratio Rank of AKBA is 3838Sharpe Ratio Rank
The Sortino Ratio Rank of AKBA is 4444Sortino Ratio Rank
The Omega Ratio Rank of AKBA is 4343Omega Ratio Rank
The Calmar Ratio Rank of AKBA is 3737Calmar Ratio Rank
The Martin Ratio Rank of AKBA is 3636Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


AKBA
Sharpe ratio
The chart of Sharpe ratio for AKBA, currently valued at -0.13, compared to the broader market-2.00-1.000.001.002.003.004.00-0.13
Sortino ratio
The chart of Sortino ratio for AKBA, currently valued at 0.48, compared to the broader market-4.00-2.000.002.004.006.000.48
Omega ratio
The chart of Omega ratio for AKBA, currently valued at 1.06, compared to the broader market0.501.001.502.001.06
Calmar ratio
The chart of Calmar ratio for AKBA, currently valued at -0.12, compared to the broader market0.002.004.006.00-0.12
Martin ratio
The chart of Martin ratio for AKBA, currently valued at -0.36, compared to the broader market-10.000.0010.0020.0030.00-0.36
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.43, compared to the broader market-2.00-1.000.001.002.003.004.002.43
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.44, compared to the broader market-4.00-2.000.002.004.006.003.44
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.43, compared to the broader market0.501.001.502.001.43
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.96, compared to the broader market0.002.004.006.001.96
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.23, compared to the broader market-10.000.0010.0020.0030.009.23

Sharpe Ratio

The current Akebia Therapeutics, Inc. Sharpe ratio is -0.13. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Akebia Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00December2024FebruaryMarchAprilMay
-0.13
2.43
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Akebia Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-96.33%
-0.29%
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Akebia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Akebia Therapeutics, Inc. was 99.14%, occurring on Nov 29, 2022. The portfolio has not yet recovered.

The current Akebia Therapeutics, Inc. drawdown is 96.33%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.14%Jun 23, 20142126Nov 29, 2022
-36.84%Mar 21, 201416Apr 11, 20145Apr 21, 201421
-21.82%Apr 22, 201420May 19, 201414Jun 9, 201434
-4.91%Jun 10, 20146Jun 17, 20143Jun 20, 20149

Volatility

Volatility Chart

The current Akebia Therapeutics, Inc. volatility is 20.25%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%December2024FebruaryMarchAprilMay
20.25%
3.00%
AKBA (Akebia Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Akebia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items